Overview
Mingfang Xu practices practicing medicine in Daping, China.
Their clinical expertise encompasses Esophageal Cancer, Lung Adenocarcinoma, Desmoplastic Small Round Cell Tumor, and Lung Cancer.
They are actively involved in clinical research, co-authoring 27 peer reviewed articles.
Locations
Clinical Research
Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.
Frequently Asked Questions about Mingfang Xu
Is Mingfang Xu a top-rated expert for Esophageal Cancer?
MediFind is an objective health platform that identifies experts based on real-world data. Mingfang Xu is classified as an Experienced expert for Esophageal Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.
Does Mingfang Xu participate in research or clinical trials?
Yes. Mingfang Xu has published 27 articles and abstracts on conditions like Esophageal Cancer. You can view a list of Mingfang Xu's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.
Areas of Expertise
MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.
Learn more about MediFind’s expert tiers
- Experienced
- Desmoplastic Small Round Cell Tumor
- Esophageal CancerXu isExperienced. Learn about Esophageal Cancer.
- Lung AdenocarcinomaXu isExperienced. Learn about Lung Adenocarcinoma.
- Lung CancerXu isExperienced. Learn about Lung Cancer.
- Non-Small Cell Lung Cancer (NSCLC)